Barclays sees ‘significant’ upside potential in Regenxbio, ups target to $88

Barclays analyst Gena Wang raised her price target for Regenxbio to $88 from $83 after speaking to a legal expert and reiterates an Overweight rating on the shares. The analyst sees “significant” upside potential from current share levels. She now expects additional AVXS-101 royalties from the European Union as well as a higher price for the drug. Further, Wang sees a high probability of positive RGX-314 data from the 4th dose cohort in wet age-related macular degeneration in Q2 of 2019.
https://thefly.com/landingPageNews.php?id=2838531